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Nuclear accumulation of p53 correlates significantly
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Summary Recent studies have suggested a p53-independent expression of p21WAF1/CIP1. We investigated the correlation between p53
overexpression and the expression of p21WAF1/C1P1 in 57 patients with pancreatic adenocarcinoma. By means of reverse transcription and
polymerase chain reaction (RT-PCR), we examined the mRNA levels of WAFl/CIPl and compared them with the p53 status in 20 patients
and in a further six pancreatic tumour cell lines. In pancreatic cancer tissues, immunohistological evaluation revealed a significant correlation
between active p53 and p21WAF1/CIP1 (P < 0.005) as well as WAFl/CIPl mRNA expression (P < 0.005). This coherence was also evident in
human pancreatic carcinoma cell lines. The analysis of p53 and p21WAFi/cPi1 expression in relation to clinicopathological features revealed a
significant correlation between p53 overexpression and tumour stage, tumoursize, grading and lymph node metastases, whereas p21WAF1/CPi1
expression correlated only with tumour size. We conclude that the expression of p21WAFi/CIPi normally depends on active p53, but that there
may also exist p53-independent pathways of induction that reduce the correlation of p21 WAFl/CPil to clinicopathological features.
Keywords: pancreatic cancer; pancreatic cancer cell line; p53; WAFl/CIPl
Inactivation of the p53 tumour-suppressor gene is a frequent
genetic abnormality in human cancers (Hollstein et al, 1991). The
wild-type p53 gene encodes a 53-kDa nuclear phosphoprotein that
is involved in the regulation of the cell cycle and apoptosis. Its
abnormalities are thought to contribute to tumour development
(Kastan et al, 1992). Since the finding thatp53 could bind to DNA
in a sequence-specific manner and activate othergenes (Kern et al,
1991; Vogelstein et al, 1992), the downstream regulation of the
p53-suppressing function has been vigorously investigated.
p21WAFI/cIPl was originally described as a potent inhibitor ofcyclin-
dependent kinases (Harper et al, 1993) and at the same time was
reported as being aMr 21 000 protein transcriptionally activated by
wild-typep53 (el Deiry et al, 1993). Subsequent studies supported
this p53-dependent expression of p21wAF1/cIPI (Kern et al, 1991;
el Deiry et al, 1994). However, recent studies have suggested that
there is a p53-independent pathway to induce the expression of
p21WAF1/cIPI in muscle and other terminally differentiating cells
(Parker et al, 1995) in pancreatic carcinoma (DiGiuseppe et al,
1995) and in leukaemic cells (Schwaller et al, 1995).
In pancreatic cancer, several investigators have reported a muta-
tion frequency of 33-44% (Casey et al, 1993; Scarpa et al, 1993).
To date, with regard to the expression ofp21WAFI/cIPl in pancreatic
cancer, only a single report has been published that indicates the
possibility of a p53-independent pathway (DiGiuseppe et al,
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1995). In the present study, we investigated the correlation
between p53 overexpression and the expression of p21WAFi'CIPl as
well as p21WAFi/cIPl messenger RNA (mRNA) levels in pancreatic
ductal adenocarcinoma tissues and pancreatic cancer cell lines.
Furthermore, we were able to induce WAFl/CIP1 in a cell line
containing mutant p53 under serum starvation or hypoxic condi-
tions. Our results demonstrate a statistically significant correlation
between p21wAF/cI'Pl and active p53 in human pancreatic cancer,
supporting the hypothesis that the suppressor function of p53
could be mediated through the induction ofWAFI/CIPI (el Deiry
et al, 1993; Harper et al, 1993).
MATERIALS AND METHODS
Patients and tissues
The group ofpatients with ductal adenocarcinomas ofthe pancreas
included 57 patients who had undergone a pancreaticoduodenec-
tomy orleft resection ofthe pancreas atthe Department ofGeneral
Surgery, University ofUlm. The mean age ofthe patients was 61.7
years, with a range from 39 to 86 years. Tissues were collected
immediately after surgical removal, snap-frozen in liquid nitrogen
and stored at-80°C, orthey were fixed in 4% formalin for 1 day at
room temperature, processed and embedded in paraffin.
Pancreatic cancer cell lines and culture condition
Human pancreatic adenocarcinoma cell lines Capan-1, Capan-2,
AsPC-1, BxPC-3 and MIA PaCa-2 were obtained from the
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299Table 1 Correlation between p53 overexpression and p21 protein expression
in 57 cases of pancreatic carcinoma (P< 0.005)
WAFl/CIPl protein expression
p53 accumulation Positive Negative Total
Negative 22 12 34
Positive 6 17 23 (40%)
Total 28 (49%) 29 57
A
A
Figure 2 Immunohistochemistry of pancreatic ductal adenocarcinoma tissue
with p53 overexpression. p53 staining showed a clear nuclear p53
accumulation (A) whereas p21WAFl/cIPl was not detectable at corresponding
sites (B)
Figure 1 Immunohistochemistry of serial sections of pancreatic ductal
adenocarcinoma tissue with negative p53 staining. No p53 staining was
achieved (A) whereas p21WAF1/CIP1 was expressed at corresponding sites (B)
American Type Culture Collection (Rockville, MD, USA), and
PMH2/89 was established in our laboratory. Cell lines were incu-
bated in RPMI-1640 medium (GIBCO BRL) supplemented with
10% heat-inactivated fetal bovine serum and 0.5% penicillin and
streptomycin in a humidified incubator at 37°C in an atmosphere
of 5% carbon dioxide and 95% air. Approximately 1 x 106 cells of
each cell line were enzymatically harvested and were subjected to
isolation of mRNA. For further investigation, Ix106 BxPC3 cells
in each 10-cm Petri dish were cultured with 7 ml of medium for
48 h. Three dishes containing 1 x 106 cells were incubated under
different conditions: in the control sample, medium was changed
at 24 h; in the second sample, medium was not changed for 48 h;
and in the third one, medium was not changed for48 h and air was
replaced with 100% carbon dioxide gas to displace oxygen and
induce hypoxic conditions. After a 48-h incubation, 1 x 106 cells
of each dish were harvested and used for extraction of mRNA or
protein samples.
Immunohistochemistry
Consecutive 5-gm-thick paraffin-embedded sections were placed
on 1% silane-coated slide glasses and were boiled up in 0.2%
citrate buffer for 20 min. The two specific monoclonal antibodies
DOl and WAFI (Oncogene Science, MA, USA), which recognize
human p53 protein or WAFI/CIPI protein (p2IWAF/lCIPI), respec-
tively, were used for immunohistochemical staining. Optimal
results for DOI were obtained at an antibody dilution of 1:500 and
for p2IWAFI/cIPl at an antibody dilution of 1:25. The primary anti-
body was detected with a biotinylated anti-mouse IgG secondary
antibody and streptavidin-peroxidase complex (Dako, Denmark),
followed by incubation with diaminobenzidine tetrahydrochloride
as the substrate. The slides were counterstained with Mayer's
haemalaun. On the basis of microscopic observation, staining for
both p53 and p2IwAFl/cIPl were graded as absent, focal or diffuse.
Enzyme-linked immunosorbent assay (ELISA)
Protein lysates were extracted from 100 mg of frozen pancreatic
adenocarcinoma tissues using lysis buffer(50 mM Tris-HCl, 150 mM
sodium chloride, 10 mM EDTA, 1% nonylphenyl-polyethylene
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Figure 3 Quantitative p53 and WAFl/CIPl determination in pancreatic carcinoma tissues in relation to the immunohistological results. Tissues with a p53
overexpression in immunohistochemistry showed significantly higher p53 levels in ELISA than p53-negative tissues (P= 0.001). Similar results were obtained in
p21 WAF1/CIPI tissue concentrations compared with immunohistology (P= 0.002)
Table 2 Correlation between p53 overexpression and WAFl/CIPl protein and mRNA expression in 20 cases of pancreatic carcinoma
WAF1/CIPImRNA expression WAFl/CIPl protein expression
p53 accumulation Positive Negative P-value Positive Negative P-value
Negative 13 2 7 8
Positive 1 4 0 5
Total 14 6 P< 0.005 7 13 P< 0.05
glycol, 100 mm phenyl methyl sulphonyl fluoride, 100 mm sodium
orthovanadate). The protein concentrations were adjusted at
10 mg ml with lysis buffer. For detection ofp53 and p2lwAFIcIm,
sandwich enzyme immunoassays (Pantropic p53 quantitative
ELISA and p2lwAFI/cwI ELISA: Oncogene Science, MA, USA)
were used, according to the manufacturer's instructions.
Western blot analysis
For Western blot analysis, 1 x 106 cells of each sample were
washed three times with phosphate-buffered saline (PBS) and
protein was extracted as described above. After denaturation at
95°C for 5 min, 100 gg of protein per lane were electrophoresed
on a sodium dodecyl sulphate (SDS)-polyacrylamide gel and
transferred to nitrocellulose membranes. The membranes were
blocked with PBS containing 5% dried milk and 0.1% Tween-20
and then probed with the p53 monoclonal antibody DO-1
(Oncogene Science). After washing in PBS containing 0.1%
Tween-20 and subsequent incubation with horseradish peroxidase-
linked anti-mouse second antibody, specific complexes were
detected using a chemiluminescent technique (ECL, Amersham
Life Science).
Reverse transcription and polymerase chain reaction
Messenger RNA (mRNA) was isolated from 100 mg of frozen
tissue or 1 x 106 cells of trypsinized cell line using a guanidinium
thiocyanate method and oligo(dT)-cellulose column chromatog-
raphy (QuickPrep Micro mRNA Purification Kit, Pharmacia
Biotech) and dissolved in.the elution buffer provided in the kit in a
final volume of30 ul.
Complementary DNA (cDNA) was prepared by reverse transcrip-
tion (RT) ofmRNA (5 g1) using SuperScript RT RNAase H-Reverse
Transcriptase (GIBCOBRL)anddilutedwithdistilled waterin afinal
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Figure 4 RT-PCR of WAFl/CIPl mRNA of pancreatic ductal adenocarcinoma tissues. The five tissues with wild-type p53(as confirmed by SSCP, data not
shown) exhibited a clearly positive WAFl/CIPl PCR signal, whereas only one out of five tissues with p53 mutations (as confirmed by SSCP) exhibited a
WAFl/CIPl PCR signal (OD, organ donor)
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Figure 5 Western blot of p53 and RT-PCR of p21 WAF'/c'Pl of pancreatic adenocarcinoma cell lines. Wild-type p53cell lines showed no detectable p53 levels in
Western blot but did show signals in WAFl/CIPl RT-PCR, whereas mutant p53cell lines showed an overexpression of p53 in Western blot but no signal in
WAFl/CIPl RT-PCR
volume of 50 ,ul. WAFl/CIPI sequences were amplified using the
following primers: 5'-AGGATCCATGTCAGAACCGGCTGG-3'
and5'-CAGGATCCTGTGGGCGGATTAGGGCT-3'. A6-gl aliquot
ofcDNA was amplified with 0.125 gM of each primer in a reaction
mix comprising 4 pl of 10 x PCR buffer, 2.5 mm dNTPs and 5 units
of Taq polymerase (Perkin Elmer) in a final volume of 40 g1.
Following denaturation at 94°C for 3 min, 31 cycles ofamplification
consisting ofdenaturation (1 min at94°C), annealing (1 min at60°C)
and elongation (1 min at 72°C) were followed by a final extension
reaction at 72°C for 5 min. The 520-bp PCR products were elec-
trophoresed on 1.25% small DNA agarose gels containing ethidium
bromide andvisualized underultraviolet light. ,B-Actin wasused as an
internal standard in each experiment to confirm equal loading ofthe
gel, according to arecentlypublishedprotocol (du-Breuil etal, 1993).
Statistical analysis
Results are expressed as mean values [± standard error (s.e.)]. For
statistical analysis, chi-square test, Fisher's exact test and unpaired
student t-test were used. Significance was defined as P < 0.05.
RESULTS
Immunohistochemistry of pancreatic cancer tissues
Immunohistochemical analysis of pancreatic ductal adenocarci-
noma tissues using DO-I antibody directed against both wild-type
p53 and mutant p53 proteins revealed positive nuclear immuno-
reactivity in 40% (23 of57). The anti-p21wAFIcIPl antibody stained
49% (28 of 57) of the tissues (Table 1). Twenty-two of the 34
patients with p53-negative staining (65%) expressed positive
nuclear staining for p21wAFlIcIPl (Figure 1). In contrast, of the 23
patients with p53-positive staining, 17 patients (74%) did not
show any immunoreactivity for p21WAFI/cIP1 (Figure 2). However,
53 kDa
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Figure 6 Western blot of p53 and RT-PCR of WAFl/CIPl of BxPC3 under
conditions of serum starvation and hypoxia. Serum starvation alone (S) as
well as hypoxia plus serum starvation (SH) led to an increase of p53 protein
and WAFl/CIPl mRNA compared with control (F, fresh medium)
positive staining for p2lwAFl/c'Pl was detectable in six patients
(26%) with p53 overexpression. Statistical analysis of these data
indicated that the expression ofp21wAFl/cIIl correlated significantly
with p53 protein overexpression in pancreatic ductal adeno-
carcinoma tissues (P < 0.005).
ELISA analysis of pancreatic cancer tissues
ELISA analysis for both p53 and p21WAFl/CIIl were performed in 20
pancreatic adenocarcinoma tissues. The mean p53 level in the
samples with positive immunoreactivity for DOI antibody was
1390 ± 630 pg ml-' and in the samples with negative immuno-
reactivity was 100 ± 80 pg ml-'. The mean p21wAF1/cIP1 level in the
samples with positive immunoreactivity for p2lwAF1/cIP1 antibody
was 4.9 ± 0.8 U ml-', while in the samples with negative immuno-
reactivity the mean level was 1.9 ± 0.4 U ml-' (Figure 3). A statis-
tical significance was noted between immunohistochemistry and
ELISA analysis in bothp53 (P <0.001) andp21W,l(Il'l (P <0.002).
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Table 3 Clinicopathological features of p21 and p53 expression
p53 p21
Negative Positive P-value Negative Positive P-value
Total 34 23 29 28
Sex
Male 19 10 14 15
Female 15 13 0.25 15 13 0.45
Stage (UICC)
Stage and 11 12 1 7 6
StagelIlI 17 20 1 and 11 vslIl and IV 18 19 and 11 vslIl and IV
Stage IV 5 2 0.005 4 3 0.8
Tumour primary
Ti 5 0 2 3
T2 20 8 Tl andT2vsT3 10 18 Tl andT2vsT3
T3 9 15 0.004 17 7 0.01
Lymph nodes
Negative 13 1 7 7
Positive 21 22 0.003 22 21 0.93
Metastases
Negative 29 21 25 25
Positive 5 2 0.49 4 3 0.72
Grade
Gl 2 0 1 1
G2 25 11 Gl and G2vsG3 16 20 Gl andG2vsG3
G3 7 12 0.014 12 7 0.15
Survival (months) 16 10.5 0.08 12 15 0.14
G, grade (Gl, well differentiated; G2, moderately differentiated; G3, undifferentiated).
RT-PCR analysis of pancreatic cancer tissues
In order to investigate whether there was a correlation between
negative p53 immunoreactivity and WAFl/CIP1 mRNA expres-
sion, RT-PCR analyses were carried out in 20 pancreatic adenocar-
cinoma tissues. Of the 15 tissues not overexpressing p53 protein,
13 tissues (87%) exhibited WAFl/CIP1 mRNA signals, including
seven tissues with positive p2lwAF'CIPl staining (Table 2). On the
otherhand, ofthe five tissues overexpressing p53 protein, only one
tissue revealed a positive WAFl/CIP1 mRNA signal and none of
these tissues showed p2IwAf1/cIP1 (Figure 4). Statistical analysis of
these data also indicated a significant correlation of WAFl/CIP1
mRNA expression with negative p53 immunoreactivity in
pancreatic ductal adenocarcinoma tissues (P < 0.005).
RT-PCR analysis of pancreatic cancer cell lines
Six human pancreatic adenocarcinoma cell lines Capan-2, AsPC-
1, PMH2, Capan-l, BxPC-3 and MIA PaCa-2 were used for the
investigation of the WAFl/CIP1 mRNA expression. In Capan-1,
BxPC-3 and MIA PaCa-2, p53 mutations in exon 5, exon 6 and
exon 7 were confirmed by single-strand conformation polymor-
phism (SSCP) respectively. In the other cell lines, nop53 mutation
was detectable (data not shown). The three cell lines with wild-
type p53, i.e. Capan-2, AsPC-1 and PMH2, exhibited clear PCR
signals of amplified WAFl/CIP1 cDNA, whereas the cell lines
bearing mutant p53, i.e. Capan-1, BxPC-3 and MIA PaCa-2,
showed only faint or no PCR signals (Figure 5).
Induction of WAFl/CIPl in the pancreatic carcinoma
cell line BxPC-3
To further investigate the induction of p21WAFI/CIPi, we cultured
BxPC-3 containing mutant p53 under three different conditions:
with fresh medium (control, F), with medium left for 48 h (S) and
with medium left for 48 h in an hypoxic, hypercapnic atmosphere
of 100% carbon dioxide (SH). In Western blot analysis for p53,
both sample S and sample SH exhibited distinct accumulation of
p53 protein compared with the control sample F. RT-PCR analysis
also revealed an increasing expression of WAFl/CIPl mRNA in
the samples S and SH (Figure 6).
Clinical correlations of p53 and p21WAF1/cIP1 expression
in pancreatic cancer
Similar to previous reports (Pellegata et al, 1994; Gansauge et al,
1996), p53 overexpression was significantly more frequent in
advanced stages (UICC stage III and IV), tumours thathad already
infiltrated adjacent structures (T3) and had metastasized in
regional lymph nodes (NI). p53 overexpression was also signifi-
cantly more often observed in undifferentiated tumours (G3)
(Table 3). These correlations were also reflected in terms of
patients' survival (p53 positive, 10.5 months; p53 negative, 16
months). Although p53 overexpression correlated significantly
with absent expression ofp2lwA-F1cIP1 (P < 0.005), correlations of
p21 WAFi/CIPi expression to clinicopathological features were
reduced compared with p53 overexpression; the only significant
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correlation of p21WAF1/CIP1 was found with the T stage. p21w F1/cwl
was significantly more frequently found in tumours that had not
infiltrated adjacent structures (Table 3).
DISCUSSION
p21WAFI/CIPI seems to be essential in the p53-mediated arrest ofthe
cell cycle in response to DNA damage (Xiong et al, 1993; Dulic et
al, 1994; el Deiry et al, 1994). Although the WAF1/CIP1 promoter
has a p53 binding site and WAF1/CIPl transcription is activated
by wild-type p53 (el Deiry et al, 1993), WAF1/CIP1 can also be
activated by p53-independent factors, as p21wAFl/cW1l is also
inducible in p53-null cell (Michieli et al, 1994). A better under-
standing of cell cycle regulation and apoptotic mechanisms in
cancer cells in particular would improve anti-cancer therapy as
many tumour cells that lack functional p53 are not able to undergo
apoptosis in response to DNA-damaging drugs or radiation
(Fisher, 1994). In pancreatic cancer, several groups have examined
the status of p53, either by sequencing the gene or by immuno-
histochemical assessment of accumulation of the p53 protein
(Barton et al, 1991; Casey et al, 1993; Lee et al, 1993; Scarpa
et al, 1993; Pellegata et al, 1994; Redston et al, 1994; DiGiuseppe
et al, 1995; Gansauge et al, 1996).
Immunohistochemical detection ofp53 is based on the evidence
that the p53 protein in normal adult tissues and in cancer tissues
with the wild-typep53 gene has a half-life ofabout 20 min (Finlay
et al, 1988), whereas mutant p53 can be stable for hours. As
immunohistochemistry alone is only an approximation to the real
mutation rate, it may underestimate the mutation frequency ofthe
p53 gene, especially with regard to deletions or non-sense muta-
tions in the p53 gene that do not lead to p53 immunoreactivity
(Borresen et al, 1991). In some cases this could probably explain
why some tissues that seem to be wild type in immunohistochem-
istry do not correspond to the expected p21WAFl/CIPl expression. On
the other hand recent reports have shown that the accumulation of
p53 is not always due to mutations in the gene (Bourdon et al,
1995), implying that stabilization of the p53 protein can also lead
to an overexpression of p53 as shown by others (Wynford-
Thomas, 1992). However, many comparative studies have shown
that p53 overexpression is a good approximation to the real muta-
tion rate (Hall et al, 1991; Melhem et al, 1995; Nishio et al, 1996)
with approximately 90% concordance between immunostaining
and gene analysis (Nishio et al, 1996) and a specificity ofimmuno-
histochemistry of 91% (Melhem et al, 1995). In addition, the
immunohistochemical evidence of the p21wAF/ClIPi expression
could depend on the mutational status of the WAFI/CIPl protein
itself. However, WAF1/CIP1 alterations seem to be rare in human
malignancies (Shiohara et al, 1994).
In the present series of surgically resected pancreatic adeno-
carcinoma tissues, p53 negativity in immunohistochemistry corre-
lated not only with p21WAF1c/IPl expression (P < 0.005) but also
with WAF1/CIP1 mRNA expression (P < 0.005), which supports
the hypothesis that wt p53 transactivates the WAFl/CIP1 gene (el
Deiry et al, 1993; Dulic et al, 1994). However, in 11% (6/57) ofthe
cases investigated, p21 WAFI/CIPI protein was immunohistochemi-
cally detectable despite a concomitant p53 accumulation, pointing
to existing p53 mutations or at least to p53 inactivation; either
p21wAFI/ClIP expression was induced in ap53-independent pathway
(Michieli et al, 1994; Akashi et al, 1995) or the underlying p53
mutations in some cases still permitted the transactivation of the
WAF1/CIPl gene.
In recent approaches it has been shown that not all mutations of
p53 correlate with a loss of transactivation activity (Ory et al,
1994). In general it has been assumed that mutated p53 proteins
exert a dominant negative effect on wtp53 functions. Forrester and
colleagues (1995) recently reported that these effects could be cell-
type dependent up to a minimal dominant negative effect oftrans-
fectant mutants on co-transfected wt p53 (Forrester et al, 1995);
although it is possible that an up-regulation of wtp53 leads to the
transactivation of the WAFI/CIPI gene as it is known that p53
levels increase under serum starvation conditions in different cell
types. In our cell line experiments, we could demonstrate an up-
regulation of p53 under serum starvation conditions accompanied
by an increase of WAFI/CIPI mRNA and p21wAFl/cIPl in the cell
line BxPC 3, which is mutated in thep53 gene (Barton et al, 1991).
The analysis ofp53 andp21wwAFl/cPl inrelation toclinicopatholog-
ical features revealed a significant correlation between p53 over-
expression and tumour stage as well as tumour size, grading and
lymph node metastases, as also shown elsewhere (Pellegata et al,
1994; Gansauge et al, 1996). p53 accumulation seems to correlate
with poorprognosis (10.5 vs 16 months), although in our study this
relationship did not reach statistical significance. As WAFI/CIPI is
a downstream effector of p53 and is induced in G1 arrest and apo-
ptosis (el Deiry et al, 1994), which mediates growth-regulatory
functions ofp53, one would expect p21wAFl/cIPl to be a supplemen-
tary factor fordescribing moreprecisely the effects ofp53 than does
p53 accumulation concerning clinicopathological features.
However, analysis of p2lwAF1/cIP1 showed only a poor correlation
between protein expression andclinical outcome despite the signifi-
cant correlation between p53 and p21wAF1/crP1 expression, which
implies the possibility of bypassing the normally p53-dependent
p2lwAF1/cWP1 induction under some physiological conditions in
pancreatic carcinoma. As the p2lwAF1/cmP1 increase occurring under
these appropriate conditions could be temporary, the immunohisto-
chemical expression of p2lwAF1/cLP1 fails to correlate with clinical
data but not in the same manner as p53 overexpression, which is
mainly because ofpersistent genetic changes.
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